ArticleAdvanced pharmaceutical bulletin2025

Safety and Feasibility of Blockade of NK Group-2 Member-A Receptor in Natural Killer Cells Combined with Cetuximab Antibody in Patients with Advanced Gastric Adenocarcinoma.

Maryam Samareh-Salavatipour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.